Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Neuromodulation in the Clinical Treatment of Psychiatric Disorders
share announcement

Neuromodulation in the Clinical Treatment of Psychiatric Disorders

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Clinical Medicine, Cell, and Organism Physiology".

Deadline for manuscript submissions: closed (1 December 2023) | Viewed by 9042

Special Issue Editor

Dr. Wei Zheng

E-Mail Website
Guest Editor
Department of Psychiatry, the Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, China
Interests: depression; neuromodulation; transcranial magnetic stimulation; transcranial direct current stimulation; ketamine; electroconvulsive therapy; systematic review; meta-analysis

Special Issue Information

Dear Colleagues,

Neuromodulation techniques, including transcranial magnetic stimulation (TMS), magnetic seizure therapy (MST), electroconvulsive therapy (ECT), theta burst stimulation (TBS), transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), vagus nerve stimulation (VNS) and deep brain stimulation (DBS), have been widely applied in the treatment of major psychiatric disorders, such as major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia, in clinical practice. This Special Issue of the Journal of Personalized Medicine aims to highlight the current state of the science and showcase some of the latest findings in the field of neuromodulation in the clinical treatment of psychiatric disorders and will comprise original research articles, reviews, systematic reviews and meta-analyses.

Dr. Wei Zheng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • depression
  • neuromodulation
  • transcranial magnetic stimulation
  • transcranial direct current stimulation
  • transcranial alternating current stimulation
  • ketamine/esketamine
  • electroconvulsive therapy
  • vagus nerve stimulation
  • deep brain stimulation
  • systematic review
  • meta-analysis

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

9 pages, 253 KiB  
Article
Omega-3 Fatty Acids Supplementation in the Treatment of Depression: An Observational Study
by Seema Mehdi, Kishor Manohar, Atiqulla Shariff, Nabeel Kinattingal, Shahid Ud Din Wani, Sultan Alshehri, Mohammad T. Imam, Faiyaz Shakeel and Kamsagara L. Krishna
J. Pers. Med. 2023, 13(2), 224; https://doi.org/10.3390/jpm13020224 - 27 Jan 2023
Cited by 8 | Viewed by 4403
Abstract
Depression is a common mood disorder characterized by persistent sadness and loss of interest. Research suggests an association between the inclusion of omega-3 fatty acids in the diet and a reduced risk for depression. The present study evaluated the effectiveness of omega-3 fatty [...] Read more.
Depression is a common mood disorder characterized by persistent sadness and loss of interest. Research suggests an association between the inclusion of omega-3 fatty acids in the diet and a reduced risk for depression. The present study evaluated the effectiveness of omega-3 fatty acid supplements in alleviating depressive symptoms in patients with mild to moderate depression. A total of 165 patients suffering from mild to moderated depression were randomized to receive omega-3 fatty acid supplementation, an antidepressant (single agent), or a combination of an antidepressant and omega-3 fatty acid supplementation. The clinical features of depression were assessed using the Hamilton Depression Rating Scale (HDRS) during the follow-up period. A statistically significant improvement in depressive symptoms was observed from baseline to first, second and third follow-ups within each treatment arm as measured by HRDS scores (p = 0.00001). Further, the HDRS scores at the third follow-up were significantly lower in patients on combination therapy of omega-3 fatty acid supplement and antidepressants (arm-3) than the patients on the omega-3 fatty acid supplement alone (arm-1) [Q = 5.89; p = 0.0001] or the patients taking an antidepressant alone (arm 2) [Q = 4.36; p = 0.0068]. The combination of an omega-3 fatty acid supplement and an antidepressant elicited significantly higher improvement in depressive symptoms than the supplement or the antidepressant alone. Full article
(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)

Other

Jump to: Research

11 pages, 589 KiB  
Brief Report
A Systematic Review of Intermittent Theta Burst Stimulation for Neurocognitive Dysfunction in Older Adults with Schizophrenia
by Xinyang Zhang, Xinhu Yang, Zhanming Shi, Rui Xu, Jianqiang Tan, Jianwen Yang, Xiong Huang, Xingbing Huang and Wei Zheng
J. Pers. Med. 2023, 13(3), 485; https://doi.org/10.3390/jpm13030485 - 08 Mar 2023
Cited by 2 | Viewed by 1134
Abstract
Objective: Neurocognitive dysfunction is thought to be one of the core clinical features of schizophrenia, and older adults with schizophrenia exhibited greater overall cognitive deficits than younger adults. The aim of this systematic review was to examine the neurocognitive effects of intermittent theta [...] Read more.
Objective: Neurocognitive dysfunction is thought to be one of the core clinical features of schizophrenia, and older adults with schizophrenia exhibited greater overall cognitive deficits than younger adults. The aim of this systematic review was to examine the neurocognitive effects of intermittent theta burst stimulation (iTBS) as an adjunctive treatment for older adults suffering from schizophrenia. Methods: Randomized double-blinded controlled trials (RCTs) investigating the neurocognitive effects of adjunctive active iTBS versus sham iTBS in older adults with schizophrenia were systematically identified by independent investigators searching Chinese and English databases. Results: Two double-blinded RCTs (n = 132) compared the neurocognitive effects of adjunctive active iTBS (n = 66) versus sham iTBS (n = 66) in patients that fulfilled the inclusion criteria of this systematic review and were analyzed. One RCT found significant superiority of active iTBS over sham iTBS in improving neurocognitive performance in older adults with schizophrenia. In the other RCT, the findings on the neurocognitive effects of iTBS as measured by three different measurement tools were inconsistent. The dropout rate was reported in the two RCTs, ranging from 3.8% (3/80) to 7.7% (4/52). Conclusion: There is preliminary evidence that adjunctive iTBS may have some beneficial effects in the treatment of neurocognitive function in older patients with schizophrenia. Future RCTs with larger sample sizes focusing on the neurocognitive effects of adjunctive iTBS in older adults with schizophrenia are warranted to verify these findings. Full article
(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)
►▼ Show Figures

Figure 1

11 pages, 1227 KiB  
Brief Report
Comparison of Efficacy and Safety of Magnetic Seizure Therapy and Electroconvulsive Therapy for Depression: A Systematic Review
by Dong-Bin Cai, Xin-Hu Yang, Zhan-Ming Shi, Sha Nie, Rui Xu, Xiu-De Qin, Xiong Huang, Xing-Bing Huang and Wei Zheng
J. Pers. Med. 2023, 13(3), 449; https://doi.org/10.3390/jpm13030449 - 28 Feb 2023
Cited by 1 | Viewed by 1225
Abstract
Objectives: As a new physical therapeutic technique, magnetic seizure therapy (MST) has established efficacy in the treatment of depression with few cognitive side effects, and thus appears to be a potential alternative to electroconvulsive therapy (ECT). The findings of randomized controlled trials (RCTs) [...] Read more.
Objectives: As a new physical therapeutic technique, magnetic seizure therapy (MST) has established efficacy in the treatment of depression with few cognitive side effects, and thus appears to be a potential alternative to electroconvulsive therapy (ECT). The findings of randomized controlled trials (RCTs) examining the efficacy and safety of MST versus ECT for depression are inconsistent. This systematic review of RCTs was designed with the aim of assessing the safety and efficacy of MST versus ECT for patients with depression. Methods: The WanFang, Chinese Journal Net (CNKI), EMBASE, PubMed, Cochrane Library, and PsycINFO databases were systematically searched by three independent investigators, from their inceptions to July 24, 2021. Results: In total, four RCTs (n = 86) were included and analyzed. Meta-analyses of study-defined response (risk ratio (RR) = 1.36; 95% CI = 0.78 to 2.36; p = 0.28; I2 = 0%), study-defined remission (RR = 1.17; 95% CI = 0.61 to 2.23; p = 0.64; I2 = 0%), and the improvement in depressive symptoms (standardized mean difference (SMD) = 0.21; 95% CI = −0.29 to 0.71; p = 0.42; I2 = 0%) did not present significant differences between MST and ECT. Three RCTs evaluated the cognitive effects of MST compared with ECT using different cognitive measuring tools, but with mixed findings. Only two RCTs reported adverse drug reactions (ADRs), but these lacked specific data. Only one RCT reported discontinuation due to any reason. Conclusions: This preliminary study suggests that MST appears to have a similar antidepressant effect as ECT for depression, but mixed findings on adverse cognitive effects were reported. Full article
(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)
►▼ Show Figures

Figure 1

15 pages, 1013 KiB  
Systematic Review
Functional Activity in the Effect of Transcranial Magnetic Stimulation Therapy for Patients with Depression: A Meta-Analysis
by Yongyan Deng, Wenyue Li and Bin Zhang
J. Pers. Med. 2023, 13(3), 405; https://doi.org/10.3390/jpm13030405 - 24 Feb 2023
Cited by 2 | Viewed by 1700
Abstract
Depression is a long-lasting mental disorder that affects more than 264 million people worldwide. Transcranial magnetic stimulation (TMS) can be a safe and effective choice for the treatment of depression. Functional neuroimaging provides unique insights into the neuropsychiatric effects of antidepressant TMS. In [...] Read more.
Depression is a long-lasting mental disorder that affects more than 264 million people worldwide. Transcranial magnetic stimulation (TMS) can be a safe and effective choice for the treatment of depression. Functional neuroimaging provides unique insights into the neuropsychiatric effects of antidepressant TMS. In this meta-analysis, we aimed to assess the functional activity of brain regions caused by TMS for depression. A literature search was conducted from inception to 5 January 2022. Studies were then selected according to predetermined inclusion and exclusion criteria. Activation likelihood estimation was applied to analyze functional activation. Five articles were ultimately included after selection. The main analysis results indicated that TMS treatment for depression can alter the activity in the right precentral gyrus, right posterior cingulate, left inferior frontal gyrus and left middle frontal gyrus. In resting-state studies, increased activation was shown in the right precentral gyrus, right posterior cingulate, left inferior frontal gyrus and left superior frontal gyrus associated with TMS treatment. In task-related studies, clusters in the right middle frontal gyrus, left sub-gyrus, left middle frontal gyrus and left posterior cingulate were hyperactivated post-treatment. Our study offers an overview of brain activity changes in patients with depression after TMS treatment. Full article
(This article belongs to the Special Issue Neuromodulation in the Clinical Treatment of Psychiatric Disorders)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop